According to her, 155 volunteers took part in clinical studies of the drug, who could have been vaccinated no earlier than 30 days before the study with any other vaccine.
“Subsequent results of clinical studies have shown that, subject to this period, it is possible to use the Convasel vaccine for revaccination after the use of the Sputnik V, EpiVacCorona and KoviVac vaccines,” she told TASS.
Earlier, the FMBA announced the launch of industrial production of the Convasel vaccine.
Post-registration trials are planned for the end of summer 2022.
Skvortsova, on the air of the Russia 24 channel, said that among those who were vaccinated with the Konvasel coronavirus vaccine as part of clinical trials, no one fell ill with COVID-19.